The Upside for Biogen Is Absolutely Wild

Earlier this week, the Food and Drug Administration gave its stamp of approval to Biogen's (NASDAQ: BIIB) new drug to treat Alzheimer's. With a price point of $56,000 for the drug, and tens of millions of possible patients around the world, the market opportunity is staggering.

Corinne Cardina, bureau chief of Healthcare and Cannabis for the Motley Fool, and Fool.com writer Taylor Carmichael run some Biogen numbers and try to make sense of it. This Fool Live segment was recorded on June 18.

Continue reading

Source Fool.com